-
31.发明公开
公开(公告)号：KR1020090016595A
公开(公告)日：2009-02-16
申请号：KR1020087030865
申请日：2006-12-08
Applicant: (주)아모레퍼시픽
IPC: A61K31/661 , C07K14/47 , C12Q1/68 , A61P17/00
CPC classification number: C12Q1/18 , G01N33/92 , G01N2405/08 , G01N2800/202 , A61K31/661 , C07K14/47
Abstract: A sphingosylphosphorylcholine(SPC) antagonist is provided to prevent and treat diseases related to the expression decrease of anti-bacterial peptide such as atopic dermatitis, and screen the SPC antagonist by analyzing the expression recover of gene or protein of the anti-bacterial peptide. The sphingosylphosphorylcholine(SPC) antagonist manufactures the medicine for restoring the expression of anti-bacterial peptide back to the normal level in mammal requiring the expression restoration of anti-bacterial peptide. The screening method of the sphingosylphosphorylcholine(SPC) antagonist comprises the steps of: treating the object with sphingosylphosphorylcholine or its derivative to inhibit expression of anti-bacterial peptide; and treating the object with the SPC antagonist candidate material, and analyzing the expression restoration level of the anti-bacterial peptide in the object.
Abstract translation: 提供鞘糖基磷酰胆碱（SPC）拮抗剂以预防和治疗与抗细菌肽如特应性皮炎的表达降低相关的疾病，并通过分析抗细菌肽的基因或蛋白质的表达恢复来筛选SPC拮抗剂。 鞘氨醇磷酰胆碱（SPC）拮抗剂在需要抗菌肽表达恢复的哺乳动物中制备了将抗菌肽的表达恢复至正常水平的药物。 鞘氨醇磷酰胆碱（SPC）拮抗剂的筛选方法包括以下步骤：用鞘糖基磷酰胆碱或其衍生物处理物体以抑制抗菌肽的表达; 并用SPC拮抗剂候选物质处理对象，分析对象中抗菌肽的表达恢复水平。
-
32.发明公开헥소사민 화합물 또는 이의 약학적으로 허용 가능한 염을포함하는, 수술 후 유착의 예방 또는 치료용 약학 조성물 有权用于预防或治疗包含十四烷基胺化合物或其药学上可接受的药物的术后粘合剂的药物组合物
公开(公告)号：KR1020080050760A
公开(公告)日：2008-06-10
申请号：KR1020060121432
申请日：2006-12-04
Applicant: (주)아모레퍼시픽
IPC: A61K31/351 , A61P41/00
CPC classification number: A61K31/7008 , A61K9/06 , A61K9/10 , A61K9/20 , A61K9/48
Abstract: A hexosamine derivative is provided to show excellent intra-abdominal fibrinous adhesion inhibitory activity, thereby being usefully used for preventing or treating post-operative adhesion. A pharmaceutical composition for preventing or treating post-operative adhesion such as intra-abdominal fibrinous adhesion comprises a hexosamine compound represented by a formula(1) or a pharmaceutically acceptable salt thereof as an active ingredient, wherein the active ingredient is selected from the group consisting of galactosamine, D-(+)-glucosamine hydrochloride, and D-(+)-galactosamine hydrochloride.
Abstract translation: 提供了一种己糖胺衍生物以显示优异的腹内纤维粘附抑制活性，从而有效地用于预防或治疗术后粘连。 用于预防或治疗术后粘连（例如腹内纤维粘连）的药物组合物包含由式（1）表示的己糖胺化合物或其药学上可接受的盐作为活性成分，其中活性成分选自 的半乳糖胺，D - （+） - 葡糖胺盐酸盐和D - （+） - 半乳糖胺盐酸盐。
-
公开(公告)号：KR1020080004075A
公开(公告)日：2008-01-09
申请号：KR1020060062558
申请日：2006-07-04
Applicant: (주)아모레퍼시픽
CPC classification number: A61K47/6951 , A61K9/0002 , A61K9/0012 , A61K9/1652
Abstract: A sustained-release porous microparticle for pulmonary delivery of a protein drug is provided to reduce destruction of microparticles by macrophages by having suitable particle size, improve stability and distribution uniformity of a protein drug, and release the drug for a long period of time without initial burst. A sustained-release porous microparticle comprises a protein drug as an active ingredient, cyclodextrin derivatives, viscous hydrophilic polymer, biodegradable polymer, sucrose acetate isobutyrate and aqueous coating materials, and has an average particle diameter of 5-100 mum. A process for preparing the sustained-release porous microparticle comprises the steps of: (1) solubilizing cyclodextrin derivatives, viscous hydrophilic polymer and a protein drug in water to prepare an inner water phase; (2) adding biodegradable polymer and sucrose acetate isobutyrate into organic solvent to prepare an organic phase; (3) mixing the inner water phase with the organic phase to prepare a first emulsion; and (4) spraying the first emulsion to an outer aqueous continuous phase containing aqueous coating materials.
Abstract translation: 提供用于肺部递送蛋白质药物的缓释多孔微粒，以通过具有适当的粒径，改善蛋白质药物的稳定性和分布均匀性，并且长时间释放药物以减少巨噬细胞对微粒的破坏，而没有初始 爆裂。 持续释放多孔微粒包含蛋白质药物作为活性成分，环糊精衍生物，粘性亲水性聚合物，可生物降解聚合物，蔗糖乙酸异丁酸酯和水性涂料，平均粒径为5-100μm。 制备缓释多孔微粒的方法包括以下步骤：（1）将环糊精衍生物，粘性亲水性聚合物和蛋白质药物溶于水中制备内水相; （2）将可生物降解的聚合物和蔗糖乙酸异丁酯加入到有机溶剂中以制备有机相; （3）将内水相与有机相混合以制备第一乳液; 和（4）将第一乳液喷涂到含有水性涂料的外部含水连续相中。
-
公开(公告)号：KR100776755B1
公开(公告)日：2007-11-28
申请号：KR1020060040588
申请日：2006-05-04
Applicant: (주)아모레퍼시픽
IPC: A61K36/9068 , A61K36/754
Abstract: 본 발명은 생강, 건강, 오수유 및 초두구로 이루어진 군으로부터 선택된 하나 이상의 추출물을 유효성분으로 함유하는 조성물에 관한 것으로서, 구체적으로 본 발명의 추출물은 뛰어난 가려움증 억제 효과를 나타내어, 염증성 피부염, 아토피성 피부염 등으로부터 유발되는 가려움증의 억제 및 완화용 조성물로 유용하게 이용될 수 있다.
생강, 건강, 오수유, 초두구, 가려움증, 소양증, 피부 외용제-
公开(公告)号：KR1020070103844A
公开(公告)日：2007-10-25
申请号：KR1020060035687
申请日：2006-04-20
Applicant: (주)아모레퍼시픽
IPC: A61K31/365 , A61K31/415
CPC classification number: A61K31/365 , A61K9/1652 , A61K9/2077 , A61K9/2081 , A61K9/5026 , A61K9/5084 , A61K45/06 , A61K2300/00
Abstract: A pharmaceutical composition comprising a lipase inhibitor and a lipophilic oil absorbent is provided to minimize side effects caused by dosage of the lipase inhibitor including oily spotting, oily feces, abdominal distension and gas, so that it is useful for prevention and treatment of obesity and hyperlipidemia. A pharmaceutical composition comprises (a) 100 parts by weight of a lipase inhibitor, (b) 10-5000 parts by weight of a lipophilic oil absorbent selected from hydrogenated castor oil, hydrogenated vegetable oil, glyceryl behenate, glyceryl palmitostearate and a mixture thereof, and (c) a pharmaceutically acceptable additive, wherein the lipase inhibitor is lipstatin, orlistat, panclicins, hesperidin, ebelactones, esterastin and its derivative, valilactone or a pharmaceutically acceptable salt. The hydrogenated vegetable oil is selected from hydrogenated cotton seed oil, hydrogenated palm oil and hydrogenated soybean oil.
Abstract translation: 提供包含脂肪酶抑制剂和亲油性油吸收剂的药物组合物，以最小化脂肪酶抑制剂的剂量引起的副作用，包括油性斑点，油性粪便，腹胀和气体，从而可用于预防和治疗肥胖症和高脂血症 。 药物组合物包含（a）100重量份脂肪酶抑制剂，（b）10-5000重量份选自氢化蓖麻油，氢化植物油，山嵛酸甘油酯，棕榈酸硬脂酸甘油酯及其混合物的亲油性油吸收剂， 和（c）药学上可接受的添加剂，其中所述脂肪酶抑制剂是脂抑素，奥利司他，胰蛋白酶，橙皮苷，内酯，酯酶及其衍生物，缬氨酸内酯或药学上可接受的盐。 氢化植物油选自氢化棉籽油，氢化棕榈油和氢化大豆油。
-
Patent Agency Ranking
公开(公告)号：KR1020070042598A
公开(公告)日：2007-04-24
申请号：KR1020050098389
申请日：2005-10-19
Applicant: (주)아모레퍼시픽
CPC classification number: A61K47/30 , A61K9/1682 , A61K38/00 , A61K47/40
Abstract: 본 발명은 단백질 약물 함유 지속방출형 고분자 미립구의 제조방법에 관한 것으로, (1) 단백질 약물, 친수성 고분자 및 사이클로덱스트린 유도체를 수성 용액 중에서 혼합하고 건조시켜 단백질 약물 혼합체를 제조하는 단계; (2) 생분해성 고분자를 함유하는 유기용매에 점성질의 수용성 고분자 수용액을 첨가하여 1차 에멀젼을 제조하는 단계; (3) 상기 1차 에멀젼에 상기 단백질 약물 혼합체를 분산시키는 단계; 및 (4) 단계 (3)에서 얻어진 에멀젼을 외부 수성 연속상에 첨가하여 2차 에멀젼을 제조한 후 2차 에멀젼 중에 생성된 고형물을 분리하는 단계를 포함하는 본 발명의 방법에 의하면, 단백질 약물을 안정하고 균일하게 함유함으로써 약물의 초기 방출을 최소한으로 억제하고 약물을 장기간 지속적으로 방출할 수 있는 지속방출형 고분자 미립구를 제조할 수 있다.
-
公开(公告)号：KR1020070032403A
公开(公告)日：2007-03-22
申请号：KR1020050086572
申请日：2005-09-16
Applicant: (주)아모레퍼시픽
IPC: A61K9/16 , A61K47/34 , A61K31/505
CPC classification number: A61K9/1682 , A61K9/1641 , A61K31/519
Abstract: Sustained release microparticles containing risperidone and a preparation method thereof are provided to avoid initial burst of risperidone, and maintain a constant release rate and effective risperidone concentration in blood for a long period of time. The method for preparing the sustained release microparticles containing risperidone comprises the steps of: (i) dissolving a biodegradable polymer in organic solvent to prepare biodegradable polymer solution having viscosity of 1.0 to 10 mPa s; (ii) adding risperidone and a release-regulating agent into the biodegradable polymer solution and mixing them to prepare an organic phase; and (iii) dispersing the organic phase in water to form oil in water(O/W) emulsion, and freeze-drying the O/W emulsion, wherein the biodegradable polymer is polylactide, polyglycolide, poly(lactide-co-glycolide)(PLGA), poly-beta-hydroxybutyl acid, polycarprolactone, polyanhydride, polyorthoester, polyurethane, poly(butyl acid), poly(valeic acid) or poly(lactide-co-carprolactone); the release-regulating agent is poloxamer, sesame oil, hydroxypropyl beta cyclodextrin, glycerin or mannitol. The amount of the release-regulating agent is 2.5-10 wt.% based on the total weight of the microparticles.
Abstract translation: 提供含有利培酮及其制备方法的缓释微粒及其制备方法，以避免利培酮的初始爆发，并长时间保持血液中恒定的释放速率和有效的利培酮浓度。 制备含有利培酮的缓释微粒的方法包括以下步骤：（i）将可生物降解的聚合物溶解在有机溶剂中以制备粘度为1.0至10mPa·s的可生物降解的聚合物溶液; （ii）将利培酮和释放调节剂加入可生物降解的聚合物溶液中并混合以制备有机相; 和（iii）将有机相分散在水中以在水（O / W）乳液中形成油，并冷冻干燥O / W乳液，其中生物可降解聚合物是聚丙交酯，聚乙交酯，聚（丙交酯 - 共 - 乙交酯） PLGA），聚-β-羟基丁酸，聚己内酯，聚酐，聚原酸酯，聚氨酯，聚（丁酸），聚（戊酸）或聚（丙交酯 - 共 - 己内酯）; 释放调节剂是泊洛沙姆，芝麻油，羟丙基β环糊精，甘油或甘露糖醇。 释放调节剂的量基于微粒的总重量为2.5-10重量％。
-
公开(公告)号：KR1020060053972A
公开(公告)日：2006-05-22
申请号：KR1020050066153
申请日：2005-07-21
Applicant: (주)아모레퍼시픽
IPC: A61K9/16 , A61K9/22 , A61K31/357
CPC classification number: A61K9/2027 , A61K9/2077
Abstract: 본 발명은 토피라메이트 서방성 제제 및 그의 제조방법에 관한 것이다.
즉, 본 발명은 토피라메이트 또는 그의 약제학적으로 허용가능한 염을 고체분산 첨가제를 사용하여 고체 분산법에 의해 1차 과립화 시키고, 얻어진 과립을 서방화 물질로 건식 혹은 습식과립법에 의해 2차 과립화 하여 얻은 이중 과립을 이용하여 제조됨을 특징으로 하는 서방성 제제에 관한 것이다.
서방성 제제, 고체 분산법, 이중과립, 토피라메이트-
公开(公告)号：KR1020050093236A
公开(公告)日：2005-09-23
申请号：KR1020040018504
申请日：2004-03-18
Applicant: (주)아모레퍼시픽
IPC: A61K9/16
CPC classification number: A61K47/593 , A61K9/0002 , A61K9/107 , A61K47/60
Abstract: 본 발명은 일반적으로 난용성 약물의 서방제에 관한 것이며, 보다 구체적으로, 점도 조절에 의한 난용성 약물 함유 서방성 미세입자의 제조방법 및 이로부터 제조된 서방성 미세입자에 관한 것이다.
-
公开(公告)号：KR1020040042152A
公开(公告)日：2004-05-20
申请号：KR1020020070317
申请日：2002-11-13
Applicant: (주)아모레퍼시픽
IPC: A61K9/50
CPC classification number: A61K9/5031
Abstract: PURPOSE: Provided are a polymeric microparticulate for the sustained release of a drug and a preparation method thereof by using the microcoagulation of the water soluble polymer, thereby increasing the amount of a drug included and inhibiting the initial over release thereof to a minimum. CONSTITUTION: A method for manufacturing a polymeric microparticulate for the sustained release of a drug comprises the steps of: preparing a polymeric solution by adding a secondary organic solvent to a first organic solvent containing biodegradable polymers and hydrophobic surfactants; dissolving a drug in an aqueous solution containing water soluble polymers and hydrophilic surfactants and adding it to the polymeric solution to give a first w/o type emulsion, wherein a polymeric microparticulate is formed; including a drug into the microparticulate; and dispersing the first w/o type emulsion into the continuous phase to solidify the polymeric microparticulate.
Abstract translation: 目的：提供一种用于持续释放药物的聚合物微粒及其制备方法，其通过使用水溶性聚合物的微凝胶，由此增加所包含的药物的量并将其初始过度释放至最小。 构成：用于制备用于药物持续释放的聚合物微粒的方法包括以下步骤：通过向含有可生物降解的聚合物和疏水性表面活性剂的第一有机溶剂中加入第二有机溶剂来制备聚合物溶液; 将药物溶解在含有水溶性聚合物和亲水性表面活性剂的水溶液中，并将其加入到聚合物溶液中，得到第一种w / o型乳液，其中形成聚合物微粒; 包括药物进入微粒; 并将第一w / o型乳液分散到连续相中以固化聚合物微粒。
-
-
-
-
-
-
-
-
-
Search Results
64
records
(took 0.04 seconds)
